Bert Tjeenk Willink,

Chairman of the Advisory Board

Engelbert (Bert) Tjeenk Willink has more than 25 years of experience within the pharmaceutical industry, most recently at Boehringer Ingelheim GmbH as a member of the Board of Managing Directors. In this role, Mr Tjeenk Willink managed the Corporate Board Division Marketing and Sales (M&S) in human pharmaceuticals and had global responsibility for the Prescription Medicines (PM) and Consumer Health Care businesses. Mr Tjeenk Willink has extensive strategic and operational experience across marketing and sales, health economics and outcomes, research, medical and business development functions. Since 2012 he holds a number of non-executive board positions at smaller pharma/biotech companies. Mr Tjeenk Willink holds a degree in Medicine from the Erasmus University Rotterdam School of Medicine and is a member of the Royal College of Pharmaceutical Industry Physicians. He is fluent in English, Dutch and German.

Jutta Heim

Observer to the Board

Jutta Heim, Ph.D. worked for more than 20 years at Ciba-Geigy/Novartis (CH and US) on the development of anti-thrombotic products. As a member of the Research Management Board she headed the Lead Discovery Center with worldwide responsibility. From 2004 to 2009, Jutta served as CSO at Basilea Pharmaceutica Ltd., focusing on anti-infectives and oncology. From 2009 to 2013, she served as CSO at Evolva SA. She holds a Professorship in Biotechnology from the University of Basel.
Jutta holds board positions at Evolva SA and Nuevolution SA and chairs the scientific advisory committee of DNDi/GARDP, a not-for-profit organisation on antimicrobial resistance.

Henry Chen,

Member of the Advisory Board

Henry Chen is a founder and Managing Partner of Delos Capital. Prior to establishing Delos in 2014, he was a Partner and Co-Head of Asia at Permira, a European private equity firm with total global committed capital of approximately €20bn. While at Permira, he worked on a number of transactions including Asia Broadcast Satellite and Galaxy Entertainment Group. Prior to joining Permira in 2008, Mr. Chen spent nine years in Investment Banking at Goldman Sachs, where he was a Managing Director and co-headed the General Industrials Group, Asia (excluding Japan). Prior to that, he was a corporate finance lawyer with Davis Polk in New York and Hong Kong. Mr. Chen holds Bachelor and Masters degrees from Harvard University, USA, and has a Juris Doctorate degree from Harvard Law School, USA

Holger Reithinger,

Member of the Advisory Board

Holger Reithinger (Chairman) is a General Partner at Forbion Capital Partners since 2010. He holds a PhD in Biochemistry, obtained at the Max-Planck-Institute of Biophysics. After his studies, Holger gained operational experience as a product development manager at Biometra/ Whatman Plc (now part of GE Healthcare). His career in Venture Capital started in 1997 as Investment Manager at Technologieholding VC GmbH, and more recently he was Partner at Global Life Science Ventures. Holger has served on the Boards of numerous life sciences companies including Epigenomics, MBT, 4SC, NeurogesX, Fibrex Medical, Agendia BV and Santaris A/S. Holger additionally holds board seats at Curetis NV, Cellnovo Group S.A.and Rigontec Gm

Stefan Herr,

Board Observer

Stefan Herr is funding partner of EMBL Ventures. Over the past 20 years, he led several venture investments in Europe and the US. Before starting EMBL Ventures, he served as Managing Director of Verivox, a 3i backed start-up company. Previously Stefan was Vice President at Heidelberg Innovation and Director Cooperations and Licensing at Hagenuk. Stefan earned his PhD in Physics from the University of Heidelberg and received additional training in law and business at the University of Hagen. He was a recipient of the Boehringer Ingelheim fellowship and is an alumni of the European Molecular Biology Laboratory Ph.D. program

Olivier Litzka,

Member of the Advisory Board

Olivier Litzka is a partner at Edmond de Rothschild Investment Partners (EdRIP) since 2006. Olivier is also a member of the boards of Autonomic Technologies Inc., Noxxon Pharma, JenaValve and SuperSonic Imagine. Up to their acquisition, he was also a member of the boards of Novexel, Endosense, Sapiens Steering Brain Stimulation Stimulation, and the public company Probiodrug. Before EdRIP, Olivier spent six years with 3i’s life science venture capital practice, before which he worked as a strategy consultant with Mercer Management Consulting. Olivier holds a PhD in molecular microbiology from the Institut für Mikrobiologie at the University of Munich

William Jenkins,

Board Observer

William Jenkins joined the pharmaceutical industry 25 years ago after a successful career in clinical medicine, medical research and as deputy of the UK’s Medicines Control Agency. His career within the industry has spanned many senior roles including Head of Worldwide Clinical Research at Glaxo and later at Ciba-Geigy. After the merger with Sandoz to create Novartis, William was Global Head of Medicine, Clinical Development & Regulatory Affairs. During his industry career William was responsible for managing the development of numerous blockbuster drugs such as Zofran, Imigran, Serevent, Diovan & Gleevec. Since 1999 he has been a consultant to the pharmaceutical industry & a member of several boards at companies achieving significant transactions including BTG, Tanox, Monogram Biosciences, Eurand, Evotec, Acambis, Glycart, Ablynx & Consort Medical as well as a chairman or member of several scientific advisory boards

Jason Rushton,

Member of the Advisory Board

B.Sc., M.Sc. Mr. Rushton is a partner at Xeraya Capital, a global venture capital firm that invests in the life sciences sector. From February 2011 to June 2016, Mr. Rushton was a director in the corporate finance advisory arm of Deloitte & Touche LLP. Prior to that, Mr. Rushton was an independent strategy consultant and an investment manager at Inventages Venture Capital Investment, Inc., an investment arm of Nestle S.A. specialising in the health care and life sciences sectors. Mr. Rushton was an associate for Merlin Biosciences Fund, L.P., a venture capital firm specialising in life science companies, and a management consultant for PA Consulting Group, a global management consulting firm. Mr. Rushton started his career at Eli Lilly and Company as a biologist.

Iain Buchanan,

Member of the Advisory Board

Iain Buchanan was appointed to the Allecra Therapeutics Advisory Board upon its formation in 2013 and brings to the company over 40 years’ experience in the Pharmaceutical and Biotech industries. Iain was Chief Executive Officer of Novexel S.A. in Paris from its creation as the anti-infective spin out of Sanofi-Aventis in 2004 until its sale in 2009. Previously, he held a variety of management positions including positions in Vertex Pharmaceuticals (Europe) Limited, Cilag A.G. and in Biogen S.A. Iain holds a Bachelor of Science in Physiology from the University of St. Andrews, Scotland and is a non-executive director of Synairgen plc

Thomas Möller,

Board Observer

M.B.A., C.P.A. After his studies, Thomas gained experience as a senior manager at PricewaterhouseCoopers in Switzerland and the US. His career in Venture Capital started in 2001 as CFO at NMT New Medical Technologies, and from 2003 at BioMed. Thomas has served on the Boards of numerous life sciences companies including idiag AG, Mediservice AG, Xiril AG, Middle Peak Medical GmbH, Thommen Medical AG and Polyphor AG. Thomas currently holds board seats at EyeSense AG, Sequana Medical AG and Inotrem SA. He has also been a General Partner at BioMedPartners AG since inception.

Tim Xiao,

Board Observer

B.Sc., FRM. Tim is a Principal at Delos Capital since its inception in 2014 and has over 10 years’ experience in investment banking and life sciences investment. Tim started his career as an investment banker at China International Capital, and later joined the Investment Banking Division of Goldman Sachs where he completed a series of transactions with total deal value over US$4 billion. Tim also serves as a Board member for Liposeuticals Inc., Curatia Medical and as an Observer for Intrinsic Therapeutics Inc.